Myriad Genetics Inc Chief Operating Officer Mark Verratti filed a Form 4 on November 9, 2026, disclosing the acquisition of 146,933 time-based stock options granted on November 6, 2026, as a retention award under the company's 2026 Employee, Director and Consultant Equity Incentive Plan.

Key Highlights

  • Grant date: November 6, 2026, with an exercise price of $5.92 per share, equal to the closing price of Myriad Genetics common stock on that date.
  • Award size: 146,933 non-qualified stock options acquired, all held directly by Verratti.
  • Vesting schedule: The options vest and become exercisable in full on November 6, 2029, subject to continued service through that date.
  • Expiration date: The options expire on November 6, 2036.
  • Award type: Described in the filing as "a one-time non-qualified stock option granted as a retention award" under the Plan.
  • Price of derivative security: $0, as reported in the filing.
  • Post-transaction holdings: Verratti beneficially owns 146,933 derivative securities following the reported transaction, held directly.

Myriad Genetics COO Receives Retention Option Grant in November 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Mark Verratti, Chief Operating Officer of Myriad Genetics Inc (NASDAQ:MYGN), received a grant of 146,933 time-based stock options on November 6, 2026. The filing identifies the award as a one-time non-qualified stock option issued under the issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. The exercise price of $5.92 per share was set equal to the closing price of the issuer's common stock on the grant date.

The filing states that the options vest and become exercisable in full on November 6, 2029, contingent on the reporting person's continued service through that date and compliance with the terms and conditions of the Plan and the applicable award agreement. The options are scheduled to expire on November 6, 2036. The underlying security is Myriad Genetics common stock, with 146,933 shares underlying the option grant. The price of the derivative security at the time of the transaction was reported as $0.

The Form 4 was filed on November 9, 2026, and signed by Justin Hunter on behalf of Mark Verratti. The filing indicates the transaction code as "A" (acquired) and classifies the ownership as direct. No transactions were reported in Table I covering non-derivative securities.

What Was Disclosed

Myriad Genetics COO Mark Verratti disclosed the acquisition of 146,933 non-qualified stock options on November 6, 2026, at an exercise price of $5.92, vesting in full on November 6, 2029, under a retention award granted pursuant to the company's 2026 equity incentive plan.